AVPR1B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1464684	1.00	20/20
SCHEMBL1465042	1.00	20/20
SCHEMBL1465094	1.00	20/20
SCHEMBL1465237	1.00	20/20
SCHEMBL1465239	1.00	20/20
SCHEMBL1465282	1.00	20/20
SCHEMBL1465362	0.96	20/20
SCHEMBL1465366	0.96	20/20
SCHEMBL1465080	0.93	20/20
SCHEMBL1465081	0.93	20/20
SCHEMBL1465011	0.91	20/20
SCHEMBL1465334	0.90	20/20
SCHEMBL1465714	0.90	20/20
SCHEMBL1465178	0.89	20/20
SCHEMBL1465188	0.89	20/20
SCHEMBL1465060	0.88	20/20
SCHEMBL1465061	0.88	20/20
SCHEMBL1464447	0.88	20/20
SCHEMBL1464995	0.87	20/20
SCHEMBL1465155	0.86	20/20

Clinical trials — most relevant to AVPR1B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cardiac Output Response to Vasopressin Infusion In Abdominal Surgery Patients Under Mechanical Ventilation	PHASE4	COMPLETED
Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease	PHASE2/PHASE3	COMPLETED
DILIPO (DILutIonal HyPOnatremia)	PHASE3	COMPLETED
Study of Stroke Related Edema Treatments	PHASE2	WITHDRAWN
Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder	PHASE2	COMPLETED
ABT-436 for Alcohol Dependence	PHASE2	COMPLETED
Effect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus and Healthy Controls	PHASE2	RECRUITING
Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls	PHASE2	RECRUITING
Efficacy and Safety of VA106483 in Elderly Males	PHASE1/PHASE2	COMPLETED
Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus	PHASE2	RECRUITING
Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment	PHASE2	COMPLETED
Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)	PHASE2	COMPLETED
The Role of Vasopressin Antagonism on Renal Sodium Handling	PHASE1	COMPLETED
Safety Study of SRX251 Capsules in Healthy Female Volunteers	PHASE1	COMPLETED
Vasopressin vs. Epinephrine During Neonatal Cardiopulmonary Resuscitation	PHASE1	ACTIVE_NOT_RECRUITING
Microcirculation Recruitment Using Albumin 20% and Terlipressin in Septic Patients	PHASE1	UNKNOWN
The Effect of Vasopressin on Glucose Regulation	nan	COMPLETED
Effect of Vasopressin on Kidney and Cardiac Function in Septic Shock	nan	UNKNOWN
Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant	nan	COMPLETED
Copeptin for Risk Stratification in Acute Stroke Patients: the CoRisk Study	nan	COMPLETED
V2 Receptor Effects on Fluid Regulation and Performance	nan	COMPLETED
Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome	nan	RECRUITING
From Micro- to Macro-vessels : Water, Salt, Heart and Kidneys	nan	COMPLETED
Effects of Intravenous [Pyr1]Apelin-13 on Healthy Volunteers With Artificially Induced SIAD	nan	COMPLETED
Urea for Treatment of Hyponatremia in Patients With SIAD Unresponsive to Fluid Restriction	nan	RECRUITING
Regulation of Arginine-vasopressin (AVP)	nan	COMPLETED
Copeptin Kinetics in Critically Ill Patients With Posterior Reversible Encephalopathy Syndrome	nan	COMPLETED
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms	nan	COMPLETED
Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease	nan	COMPLETED
Potassium, Hydration, Cardiovascular, and Kidney Study (PHACKs)	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a AVPR1B binder may also engage these)

Protein	Name	Similarity
P48974	—	0.996	P48974 →
Q9WU02	—	0.995	Q9WU02 →
Q95JG1	—	0.986	Q95JG1 →
Q95MG6	—	0.984	Q95MG6 →
Q95MH6	—	0.981	Q95MH6 →
AVPR2	Vasopressin V2 receptor	0.978	landscape →
O88721	—	0.976	O88721 →
Q00788	—	0.976	Q00788 →
P56489	—	0.974	P56489 →
P04761	—	0.973	P04761 →
Q96P88	—	0.973	Q96P88 →
O77808	—	0.973	O77808 →
Q5R949	—	0.972	Q5R949 →
P08482	—	0.971	P08482 →
P12657	—	0.970	P12657 →
CHRM1	Muscarinic acetylcholine receptor M1	0.969	landscape →
P32306	—	0.968	P32306 →
P48044	—	0.967	P48044 →
Q62463	—	0.967	Q62463 →
P56494	—	0.966	P56494 →
P97926	—	0.965	P97926 →
P56449	—	0.964	P56449 →
Q9WTV9	—	0.964	Q9WTV9 →
Q9WTV8	—	0.964	Q9WTV8 →
P32307	—	0.964	P32307 →
Q28756	—	0.963	Q28756 →
NMUR1	Neuromedin-U receptor 1	0.963	landscape →
P48043	—	0.962	P48043 →
OXTR	Oxytocin receptor	0.962	landscape →
P30560	—	0.960	P30560 →